Pharsight

Tivorbex generic

Tivorbex is an analgesic drug, specifically for pain treatment, owned by Genus. This drug, having indomethacin as its active ingredient, was first authorized for market use on 24 February, 2014.

When will Tivorbex generic be available?

The generic version of Tivorbex is likely to be released after 23 April, 2030. This is due to the expiry of its last patent on the same date.

Tivorbex uses

Tivorbex, containing indomethacin, is primarily used for the treatment of pain. indomethacin, as an active ingredient, works by reducing hormones that cause inflammation and pain in the body.

Tivorbex patent expiration

Tivorbex, a Genus drug, holds three patents, none of which have expired as of now. The last patent of Tivorbex expires on 23 April, 2030, paving the way for Tivorbex generic release. Below are the details of the patents:

Tivorbex dosage

Want to ask something?